Community Drug Board Inc
Analysis
Community Drug Board Inc is a registered charity in United States, based in Akron, OH. It received its IRS tax-exemption ruling in May 1977, 49 years ago. The IRS classifies it as a publicly supported organisation (donations from the general public) under section 501(c)(3), and contributions to it are listed as tax-deductible.
In the financial year ending June 2024, Community Drug Board Inc reported income of $15.0m and spending of $12.4m, spending 83% of its income. Across the 6 years on record, from June 2019 to June 2024, income grew from $10.9m to $15.0m (+38%), an average of +6.6% a year. The sharpest change came in the year to June 2023, when income rose by 18%. Over the whole period it spent 91% of the income it received.
Among 72,936 United States charities whose main cause is other charitable purposes and that reported income, Community Drug Board Inc sits at the 97th percentile: it is larger than about 97% of them. Against every charity in United States with reported income it ranks in the 96th percentile, and in the 97th percentile within OH. Charities of a similar size with the same main cause include Tucson Residence Foundation Inc ($15.0m), Cares of Ny Inc ($15.0m) and Augustus & James Corporation ($15.0m).
On its Form 990 for the period ending June 2024, revenue came from contributions and grants 28% and program service revenue 69% of the total. Compensation of current officers, directors and key employees was $376k (3.0% of expenses). Other salaries and wages came to $7.3m. At year end it held assets of $15.4m against liabilities of $3.4m, net assets of $12.0m. It reported 198 employees.
Income and spending
Where the income comes from
- Contributions & grants 28%
- Program services 69%
- Other 2.8%
Similar-sized charities, same cause
| Charity | Location | Income |
|---|---|---|
| Tucson Residence Foundation Inc | Tucson | $15.0m |
| Cares of Ny Inc | Albany | $15.0m |
| Augustus & James Corporation | New York | $15.0m |
| Morselife Health System Inc | West Palm BCH | $15.0m |